Australia rows back on biosimilar naming as US awaits guidance
This article was originally published in Scrip
Having been among the first to adopt a distinct naming convention for biosimilars, the Australian Therapeutic Goods Administration (TGA) has now put its policy on hold while the World Health Organization thrashes out its own guidelines for the naming of biologic and biosimilar products.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.